Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
PHASE1CompletedINTERVENTIONAL
Enrollment
3
Participants
Timeline
Start Date
September 27, 2021
Primary Completion Date
May 6, 2022
Study Completion Date
May 6, 2022
Conditions
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Interventions
DRUG
Encorafenib
oral capsule
Trial Locations (1)
510060
Sun Yat-sen University Cancer Center, Guangzhou
All Listed Sponsors
lead
Pierre Fabre Medicament
INDUSTRY
NCT05003622 - Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors | Biotech Hunter | Biotech Hunter